公开(公告)号：WO2007013480A2

公开(公告)日：2007-02-01

申请号：PCT/JP2006314715

申请日：2006-07-19

Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

IPC: G01N33/574 ,  A61K47/46 ,  A61P35/00

CPC classification number: G01N33/57423 ,  G01N2500/02

Abstract: The present invention is based on the observation that the co-activation of CDCA1 and KNTC2, and their cognate interactions, play significant roles in lung-cancer progression and that methods of inhibiting the complex can be used to treat non-small-cell lung cancer.

Abstract translation: 本发明基于观察到CDCA1和KNTC2的共激活及其同源相互作用在肺癌发展中起重要作用，抑制复合物的方法可用于治疗非小细胞肺癌 。

公开(公告)号：WO2005019475A3

公开(公告)日：2005-08-11

申请号：PCT/JP2004012411

申请日：2004-08-20

Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA

Inventor： NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158

Abstract: The present invention provides a method for inhibiting growth of a cancer cell, particularly a renal cell carcinoma, by contacting the cell with a composition composed of an HIG2 siRNA or HIG2 antibody. Methods of diagnosing renal cell cancer are also provided within the present invention.

Abstract translation: 本发明提供通过使细胞与由HIG2 siRNA或HIG2抗体组成的组合物接触来抑制癌细胞，特别是肾细胞癌生长的方法。 本发明还提供了诊断肾细胞癌的方法。

公开(公告)号：WO2005028675A3

公开(公告)日：2005-06-02

申请号：PCT/JP2004013722

申请日：2004-09-14

Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  FURUKAWA YOICHI

Inventor： NAKAMURA YUSUKE ,  FURUKAWA YOICHI

IPC: C12N15/113 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  A61K39/0011 ,  A61K2039/57 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/111 ,  C12N2310/14 ,  C12Q2600/136 ,  G01N33/57438 ,  G01N2500/00

Abstract: Objective methods for detecting, diagnosing, treating and preventing hepatocellular carcinoma (HCC) are described herein. In particular, the present invention relates to two genes up-regulated in HCC cells as compared to normal cells, referred to herein as MGC47816 and HES6. In one embodiment, the diagnostic method involves the determining the expression level of MGC47816 or HES6 that discriminate between hepatocellular carcinoma cellsand normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of HCC, methods of treating HCC, and methods for vaccinating a subject against HCC.

Abstract translation: 本文描述了检测，诊断，治疗和预防肝细胞癌（HCC）的客观方法。 特别地，本发明涉及与正常细胞相比，在本文中称为MGC47816和HES6的HCC细胞中上调的两种基因。 在一个实施方案中，诊断方法涉及确定区分肝细胞癌细胞和正常细胞的MGC47816或HES6的表达​​水平。 本发明进一步提供筛选用于治疗HCC的治疗剂，治疗HCC的方法，以及针对HCC接种受试者的方法的方法。

公开(公告)号：WO2004038045A3

公开(公告)日：2005-02-24

申请号：PCT/JP0311975

申请日：2003-09-19

Applicant: ONCOTHERAPY SCIENCE INC ,  JAPAN AS REPRESENTED BY THE PR ,  NAKAMURA YUSUKE ,  FURUKAWA YOICHI

Inventor： NAKAMURA YUSUKE ,  FURUKAWA YOICHI

IPC: C12Q1/68 ,  G01N33/574

CPC classification number: G01N33/57446 ,  A61K48/00 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2500/00

Abstract: Methods for detecting and diagnosing diffuse-type gastric cancer (DGC) are described herein. In one embodiment, the diagnostic method involves the determination of an expression level of DGC -associated gene that discriminate between DGC and normal cell. The present invention further provides methods of screening for therapeutic agents useful in the treatment of DGC, methods of treating DGC and method of vaccinating a subject against DGC.

Abstract translation: 本文描述了扩散型胃癌（DGC）的检测和诊断方法。 在一个实施方案中，诊断方法涉及确定区分DGC和正常细胞的DGC相关基因的表达水平。 本发明进一步提供筛选用于治疗DGC的治疗剂的方法，DGC治疗方法和用DGC接种受试者的方法。

公开(公告)号：WO2006090810A3

公开(公告)日：2007-03-29

申请号：PCT/JP2006303354

申请日：2006-02-17

Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  TAHARA HIDEAKI ,  TSUNODA TAKUYA ,  NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

Inventor： TAHARA HIDEAKI ,  TSUNODA TAKUYA ,  NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

IPC: C12N9/12 ,  C12Q1/68

CPC classification number: C12N9/1211 ,  C12Q1/6886

Abstract: The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 8, 67, 89, as well as peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, and having cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors comprising these peptides. The peptides of the present invention can also be used as vaccines.

Abstract translation: 本发明提供了包含SEQ ID NO：8,67,89的氨基酸序列的肽以及包含上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失或添加 ，并具有细胞毒性T细胞诱导性。 本发明还提供了用于治疗或预防包含这些肽的肿瘤的药物。 本发明的肽也可以用作疫苗。

公开(公告)号：WO2007013479A2

公开(公告)日：2007-02-01

申请号：PCT/JP2006314714

申请日：2006-07-19

Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  NAKAGAWA HIDEWAKI ,  NAKATSURU SHUICHI

Inventor： NAKAMURA YUSUKE ,  NAKAGAWA HIDEWAKI ,  NAKATSURU SHUICHI

IPC: G01N33/574 ,  C12Q1/48

CPC classification number: G01N33/57434 ,  A61K38/1709 ,  C07K14/4748 ,  C12Q1/48 ,  G01N33/573 ,  G01N2333/91051 ,  G01N2500/00

Abstract: The present application provides novel human gene ELOVL7 whose expression is markedly elevated in prostate cancers. The gene and polypeptide encoded by the gene can be used, for example, in the diagnosis of prostate cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of prostate cancer.

Abstract translation: 本申请提供了新型人类基因ELOVL7，其表达在前列腺癌中显着升高。 由该基因编码的基因和多肽可用于例如前列腺癌的诊断中，作为用于开发针对该疾病的药物的靶分子，以及用于减轻前列腺癌的细胞生长。

公开(公告)号：WO2005089735A3

公开(公告)日：2006-03-02

申请号：PCT/JP2005005621

申请日：2005-03-18

Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

IPC: C12N15/113 ,  G01N33/574 ,  C12N15/11

CPC classification number: C12N15/113 ,  C12N15/1138 ,  C12N2310/111 ,  C12N2310/53 ,  G01N33/57423

Abstract: The invention features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of a PKP3, CDCA1, CDCA8, DLX5, URLC11 or NPTX1 siRNA. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumor cell, for example lung cancer cell, particularly NSCLC.

Abstract translation: 本发明的特征在于通过使细胞与PKP3，CDCA1，CDCA8，DLX5，URLC11或NPTX1 siRNA的组合物接触来抑制癌细胞生长的方法。 治疗癌症的方法也在本发明的范围内。 本发明还包括可用于所提供的方法的产品，包括核酸序列和载体以及包含它们的组合物。 本发明还提供了抑制肿瘤细胞的方法，例如肺癌细胞，特别是NSCLC。

公开(公告)号：WO2004031413A9

公开(公告)日：2005-08-04

申请号：PCT/JP0312072

申请日：2003-09-22

Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

IPC: A61P35/00 ,  C12N15/113 ,  C12N15/12 ,  C12Q1/68 ,  A61K39/00 ,  C12N15/11 ,  G01N33/50

CPC classification number: G01N33/57423 ,  A61K31/7088 ,  C07K14/47 ,  C12N15/1135 ,  C12N2310/11 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/136 ,  G01N2800/50

Abstract: Disclosed are methods for detecting non-small cell lung cancer using differentially expressed genes. Furthermore, novel human genes whose expression is elevated in non-small cell lung cancer compared to no-cancerous tissues are provided. Also disclosed are methods of identifying compounds for treating and preventing non-small cell lung cancer.

Abstract translation: 公开了使用差异表达基因检测非小细胞肺癌的方法。 此外，提供了与非癌组织相比，在非小细胞肺癌中表达升高的新型人类基因。 还公开了鉴定用于治疗和预防非小细胞肺癌的化合物的方法。

公开(公告)号：WO2004031409A3

公开(公告)日：2005-02-24

申请号：PCT/JP0310256

申请日：2003-08-12

Applicant: ONCOTHERAPY SCIENCE INC ,  JAPAN AS REPRESENTED BY THE PR ,  NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA

Inventor： NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA

IPC: A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C12N15/12 ,  C12Q1/68 ,  G01N33/574 ,  A61K35/00 ,  G01N33/50

CPC classification number: C12Q1/6883 ,  A61K39/0011 ,  C07K14/47 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57426 ,  G01N2500/04

Abstract: Objective methods for detecting and diagnosing Chronic myeloid leukemia (CML) are described herein. In one embodiment, the diagnostic method involves the determining a expression level of CML-associated gene that discriminate between CML and nomal cell. The present invention further provides methods of screening for therapeutic agents useful in the treatment of CML, methods of treating CML and method of vaccinating a subject against CML.

Abstract translation: 本文描述了用于检测和诊断慢性骨髓性白血病（CML）的客观方法。 在一个实施方案中，诊断方法涉及确定区分CML和正常细胞的CML相关基因的表达水平。 本发明进一步提供筛选用于治疗CML的治疗剂，CML治疗方法以及针对CML接种受试者的方法。

公开(公告)号：WO2004031412A3

公开(公告)日：2004-07-15

申请号：PCT/JP0311817

申请日：2003-09-17

Applicant: ONCOTHERAPY SCIENCE INC ,  JAPAN AS REPRESENTED BY THE PR ,  NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA

Inventor： NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA

IPC: A61K38/00 ,  C07K14/47 ,  C12Q1/68 ,  G01N33/574

CPC classification number: G01N33/57438 ,  A61K38/00 ,  C07K14/47 ,  C07K14/82 ,  C12Q1/6837 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y02A90/26

Abstract: Objective methods for detecting and diagnosing pancreatic cancer (PNC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of PNC-associated gene that discriminates between PNC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of pancreatic cancer, methods of treating pancreatic cancer and method of vaccinating a subject against pancreatic cancer.

Abstract translation: 本文描述了用于检测和诊断胰腺癌（PNC）的客观方法。 在一个实施方案中，诊断方法涉及确定区分PNC细胞和正常细胞的PNC相关基因的表达水平。 本发明进一步提供筛选用于治疗胰腺癌的治疗剂的方法，治疗胰腺癌的方法以及针对胰腺癌接种受试者的方法。